Treatment with liposome-bound recombinant human tumor necrosis factor- α suppresses parasitemia and protects against Plasmodium berghei k173- induced experimental cerebral malaria in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 114-120

  Postma, N S ^b   Crommelin, D J A ^b,c   Eling, W M C ^a,b   Zuidema, J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BRAIN MALARIA; DRUG EFFECT; DRUG EFFICACY; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM BERGHEI; PRIORITY JOURNAL;

EID: 0032915598     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Alexander HR, Sheppard BC, Jensen JC, Langstein HN, Buresh CM, Venzon D Walker EC, Fraker DL, Stovroff MC and Norton JA (1991) Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest 88:34-39.
2. Blume G and Cevc G (1990) Liposomes for the sustained release in vivo. Biochim Biophys Acta 1029:91-97.
3. Carswell EA, Old LJ, Kassel RL, Greene S, Fiore N and Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3670.
4. Corti A, Fassina G, Marcucci F, Barbanti E and Cassani G (1992) Oligomeric tumor necrosis factor a slowly converts into inactive forms at bioactive levels. Biochem J 284:905-910.
5. Curfs JHAJ, Hermsen CC, Meuwissen JHETh and Eling WMC (1992) Immunisation against cerebral pathology in Plasmodium berghei infected mice. Parasitalogy 105:7-14.
6. Curfs JHAJ, Hermsen CC, Kremsner P, Neifer S, Meuwissen JHETh, Van Rooyen N and Eling WMC (1993) Tumour necrosis factor-a and macrophages in Plasmodium berghei-induced cerebral malaria. Parasitology 107:125-134.
7. Debs RJ, Düzgünes N, Brunette EN, Fendly B, Patton J and Philip R (1989) Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing anti-tumor necrosis factor antibodies. J Immunol 143:1192-1197.
8. Duncan RJS, Weston PD and Wrigglesworth R (1983) A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. Anal Biochem 132:68-73.
9. Espevik T and Nissen-Meyer J (1986) A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99-105.
10. Ferraiolo BL, Moore JA, Crase D, Gribling P, Wilking H and Baughman RA (1988) Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-α in mice. Drug Metab Dispos 16:270-275.
11. Franssen EJ, Koiter J, Kuipers CA, Bruins AP, De Zeeuw D, Kruizenga WH, Kellogg RM and Meijer DK (1992) Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. J Med Chem 35:1246-1259.
12. Grau GE, Piguet P-F, Vassalli P and Lambert P-H (1989) Tumor-Necrosis Factor and other cytokines in cerebral malaria: Experimental and clinical data. Immunol Rev 112:49-70.
13. Huang L (1992) Covalently attached polymers and glycans to alter the biodistribution of liposomes. J Lipid Res 2:289-454.
14. Jacobs P, Radzich D and Stevenson M (1996) A Th1-associated increase in tumour necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Infect Immun 64:535-541.
15. Johnson RA, Waddelow TA, Caro J, Oliff A and Roodman GD (1989) Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74:130-138.
16. Kremsner PG, Winkler S, Brandts C, Wildling E, Jenne L, Graninger W, Prada J, Bienzle U, Juillard P and Grau GE (1995) Prediction of accelerated cure in Plasmodium falciparum malaria by the elevated capacity of tumor necrosis factor production. Am J Trop Med Hyg 53:532-538.
17. Kumaratilake LM, Ferrante A and Rzepczyk CM (1990) Tumour necrosis factor enhances neutrophil-mediated killing of Plasmodium falciparum. Infect Immun 58:788-793.
18. McGuire W, Hill AVS, Allsopp CEM, Greenwood BM and Kwiatkowski D (1994) Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 371:508-511.
19. McMartin C (1992) Pharmacokinetics of peptides and proteins: Opportunities and challenges. Adv Drug Res 22:39-106.
20. Moldawer LL, Marano MA, Wei H, Fong Y, Silen ML, Kuo G, Mahogue KR, Vlassara H, Cohen H, Cerami A, Lowry SF (1989) Cachectin/tumor necrosis factor-α alters red blood cell kinetics and induces anemia in vivo. FASEB J 3:1637-1643.
21. Mori A, Duda E and Huang L (1996) Recombinant human tumour necrosis factor-α covalently conjugated to long-circulating liposomes. Int J Pharm (Amst) 131:57-66.
22. Narhi LO and Arakawa T (1987) Dissociation of recombinant tumor necrosis factor-α studied by gel permeation chromatography. Biochem Biophys Res Commun 147: 740-746.
23. Olson F, Hunt CA, Szoka F, Vail WJ and Papahdjopoulos D (1979) Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 551:295-303.
24. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB and Goeddel DV (1984) Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 312:724-729.
25. Pessina GP, Pacini A, Bocci V, Maioli E and Naldini A (1987) Studies on tumour necrosis factor (TNF): II. Metabolic fate and distribution of human recombinant TNF. Lymphokine Res 6:35-44.
26. Polder TW, Eling WMC, Curfs JHAJ, Jerusalem CR and Wijers-Rouw M (1992) Ultrastructural changes in the blood-brain barrier of mice infected with Plasmodium berghei. Acta Leiden 60:31-46.
27. Rouser G, Flusher S and Yamamoto A (1970) Two dimensional thin layer Chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5:494-496.
28. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D and Boyd MR (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827-4833.
29. Senior JH (1987) Fate and behavior of liposomes in vivo: A review of controlling factors. CAC Crit Rev Ther Drug Carrier Syst 3:123-193.
30. Smith RA and Baglioni C (1987) The active form of tumor necrosis factor is a trimer. J Biol Chem 262:6951-6954.
31. Stevenson MM and Ghadirian E (1989) Human recombinant tumour necrosis factor alpha protects susceptible A/J mice against lethal Plasmodium chabaudi AS infection. Infect Immun 57:3936-3939.
32. Storm G, Wilms HP and Crommelin DJA (1991) Liposomes and biotherapeutics. Biotherapy 3:25-42.
33. Takahashi N, Brouckaert P and Fiers W (1993) Cyclooxygenase inhibitors prevent the induction of tolerance to the toxic effects of tumour necrosis factor. J Immunother 14:16-21.
34. Takahashi N, Brouckaert P and Fiers W (1995) Mechanism of tolerance to tumor necrosis factor: Receptor-specific pathway and selectivity. Am J Physiol 269: R398-R405.
35. Taverne J, Sheikh N, De Souza JB, Playfair JHL, Probert L and Kollias G (1994) Anaemia and resistance to malaria in transgenic mice expressing human tumour necrosis factor. Immunology 82:397-403.
36. Tracey KJ and Cerami A (1994) Tumour necrosis factor: A pleiotropic cytckine and therapeutic target. Ann Rev Med 45:491-503.
37. Tsutsumi Y, Kihira T, Tsunoda S-i, Kubo K, Miyake M, Kanamori T, Nakagawa S and Mayumi T (1994) Chemical modification of natural human tumour necrosis factor-α with polyethylene glycol increases its anti-tumour potency. Jpn J Cancer Res 85:9-12.
38. Utsumi T, Hung M-C and Klostergaard J (1991) Preparation and characterization of liposomal-lipophilic tumor necrosis factor. Cancer Res 51:3362-3366.
39. Van Ostade X, Tavernier J and Fiers W (19941 Structure-activity studies of human tumour necrosis factors. Protein Eng 7:5-22.
40. Woodle MC, Storm G, Newman MS, Jekot J, Collins LR, Martin FJ and Szoka FC (1992) Prolonged systemic delivery of peptide drugs by long circulating liposomes: Illustration with vasopressin in the Brattleboro rat. Pharm Res (NY) 9:260-265.